Aspiration therapy for obesity; a safe and effective treatment

Norén, Erik; Forssell, Henrik

doi:10.1186/s40608-016-0134-0

Cited by 34 publications

(29 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A cinética da perda de peso foi avaliada em dois momentos e contextos distintos: após a remoção do balão e depois do periódo de follow-up (PFU), que variou entre 6-12 meses. Eficácia definida como perda de peso 10% após PFU de [6][7][8][9][10][11][12] 16 foram excluidos (7 por intolerancia) e 35 entraram no estudo, dos quais 83% foram seguidos durante PFU. A perda de peso média (PPM) e % de excesso de peso perdido (EPP) na altura de remoção do BIG foi de 11.94 kg e 42.16%, respetivamente; após PFU, a PPM foi de 8.25 kg e o EPP foi 30.27%.…”

Section: Introductionunclassified

“…Endoscopic modalities in the treatment of obesity can be categorized into the following: space-occupying devices (intragastric balloon [IGB], transpyloric shuttle), gastric restrictive methods (transoral gastroplasty, transoral endoscopic restrictive implant system), malabsorptive endoscopic procedures (duodenal-jejunal bypass liner, satiSphere), regulating gastric emptying (intragastric botulinum toxin injections, gastric electrical stimulation), and other therapies (aspiration therapy) [14][15][16]. Of these methods, the most commonly employed is IGB placement.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Intragastric Balloon for Obesity Treatment: Safety, Tolerance, and Efficacy

Silva¹,

Proença²,

Rodrigues³

et al. 2017

GE Port J Gastroenterol

View full text Add to dashboard Cite

Background: Obesity is an increasing worldwide problem associated with a vast number of comorbidities. Decreasing body weight by only 5-10% has been shown to slow and even prevent the onset of obesity-related comorbidities. Between pharmacological therapy and bariatric surgery a great variety of endoscopic techniques are available, the most common being intragastric balloon (IGB). The purpose of this study was to assess the safety, tolerance, and kinetics of IGBs in weight loss. The kinetics of weight loss were evaluated in 2 different contexts and phases: after the IGB's removal and after follow-up that varied between 6 and 12 months. Successful weight loss was defined as ≥10% weight loss after 6-12 months. Methods: The study included 51 patients who had undergone Orbera® IGB placement between September 2014 and February 2016. Inclusion criteria were age between 18 and 65 years; body mass index (BMI) 28-35 with severe obesity-related disorders; or BMI 35-40. The IGB was removed 6 months later. All patients were followed for a minimum period of 6-12 months. Results: Of 51 patients, 16 were excluded (7 due to intolerance) and 35 patients entered the study, of which 83% were followed for more than 6-12 months. The average weight loss (WL) and % excess WL (%EWL) after 6 months of treatment were 11.94 kg and 42.16%, respectively. At 6-12 months, after removal of the IGB, the mean WL was 8.25 kg and %EWL was 30.27%. Nineteen patients attained a WL of ≥10% the baseline value at IGB removal and 12 maintained their weight below this threshold during the 6-12 following months. Conclusions: After temporary IGB implantation in overweight or obese individuals, a WL that was ≥10% of weight at baseline was achieved in 54.3% and sustained at 6-12 months in 41.4% of participants. IGBs are an attractive intermediate option between diet and exercise programs and bariatric surgery. In general, IGB placement is a safe and well-tolerated procedure.

show abstract

Section: Introductionunclassified

Section: Introductionmentioning

confidence: 99%

Intragastric Balloon for Obesity Treatment: Safety, Tolerance, and Efficacy

Silva¹,

Proença²,

Rodrigues³

et al. 2017

GE Port J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…With the recent FDA approval of 3 IGBs (Orbera: Apollo Endosurgery, Austin, TX; ReShape Duo: ReShape Medical, San Clemente, CA; Obalon Balloon System: Obalon Therapeutics, Carlsbad, CA; see Table 1 and Figure 2) and an AT system (AspireAssist: Aspire Bariatrics, Kings of Prussia, PA), endoscopic bariatric procedures have reemerged as a viable option for the treatment of obesity. Two of the new IGBs are endoscopically placed, left for 6 months, and then retrieved 13 , 24 . In addition, there is a new IGB that is swallowed and then endoscopically removed after 3–6 months.…”

Section: Endoscopic Bariatric Proceduresmentioning

confidence: 99%

“…The follow‐up study was a prospective observational study of 25 obese patients (BMI, 35–49 kg/m 2 ) over a period of 12–24 months in a single center in Sweden 13 . Subjects were instructed to aspirate 3 times a day, 20 minutes after each major meal, for the entire study period (12–24 months) 13 . A total of 20 subjects (80%) completed the protocol to 12 months and 15 (60%) to 24 months.…”

Section: At Systemmentioning

confidence: 99%

Novel Nonsurgical Endoscopic Approaches for the Treatment of Obesity

2017

View full text Add to dashboard Cite

Globally, obesity is a leading cause of preventable death and is associated with >60 comorbid medical conditions, including 10 types of cancer that are strongly associated with body mass index. There are a number of traditional obesity treatments-for example, lifestyle management (eg, decreased caloric intake and increased expenditure), pharmacotherapy, and bariatric surgery. Recently, endoscopic approaches have emerged as a viable alternative for weight loss. Endoscopically placed intragastric balloons were introduced in the early 1980s for the treatment of medically complicated obesity but, unfortunately, had high rates of complications, such as premature deflation leading to obstruction. Despite these shortcomings, these devices have experienced a renewal, with a second generation of improved devices being approved for clinical use in 2015. In addition to the intragastric balloons, there are a number of other endoscopic approaches to weight loss that are either Food and Drug Administration approved or undergoing evaluation (aspiration therapy, duodenal jejunal bypass sleeve). The current review examines the literature available and discusses the practical clinical considerations involved.

show abstract

“…The prolonged eating rate and chewing seen in RYGB can contribute to its positive impact on satiety [77]. It's noteworthy that improved mastication was thought to contribute to efficacy of other obesity treatments such as aspiration therapy [77,78].…”

Section: The Oropharyngeal Phase Of Swallowing and Weight Loss After mentioning

confidence: 99%

Impact of Roux-En-Y Gastric Bypass Surgery on Neurohormonal and Gastrointestinal Physiology: Insights for Future Weight Loss Efforts

Hussan¹,

Ugbarugba²,

Krishna³

et al. 2017

J Obes Weight Loss Ther

View full text Add to dashboard Cite

Roux-en-Y Gastric Bypass (RYGB), is an effective weight loss intervention for patients failing conventional nonsurgical methods. Despite its popularity, only a subset of patients undergo RYGB due to its cumbersome nature. Furthermore, patients may experience nutritional deficiencies or weight regain after RYGB. This review will delineate the less known impact of RYGB on neurohormonal and gastrointestinal physiology involved in weight loss. Understanding these alterations will contribute to the development of future novel investigations targeting viable weight loss strategies.

show abstract

Aspiration therapy for obesity; a safe and effective treatment

Cited by 34 publications

References 23 publications

Intragastric Balloon for Obesity Treatment: Safety, Tolerance, and Efficacy

Intragastric Balloon for Obesity Treatment: Safety, Tolerance, and Efficacy

Novel Nonsurgical Endoscopic Approaches for the Treatment of Obesity

Impact of Roux-En-Y Gastric Bypass Surgery on Neurohormonal and Gastrointestinal Physiology: Insights for Future Weight Loss Efforts

Contact Info

Product

Resources

About